{"resourceType": "Group", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/346486", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "CTIS2024-516402-32-00 Eligibility Criteria", "assigner": {"display": "Computable Publishing LLC"}}], "name": "CTIS2024_516402_32_00_Eligibility_Criteria", "title": "CTIS2024-516402-32-00 Eligibility Criteria", "status": "active", "membership": "conceptual", "combinationMethod": "all-of", "characteristic": [{"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Age \u2265 18 years"}, "exclude": false}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Hospitalization forHE-aHUS within prior 10 days: o Presume acute renal failure (renal replacement therapy or serum creatinine \u2265 354\u03bcM). o Mechanical hemolysis including: anemia, thrombopenia, and: low haptoglobin (1,5UNL), or presence of schistocytes o Severe hypertension with systolic blood pressure >180mmHg and/or diastolic blood pressure>110mmHg o Target organ damage, including neurological involvement (notably hypertensive encephalopathy, headache, confusion, nausea, posterior reversible encephalopathy syndrome), or cardiovascular involvement (notably acute left ventricular failure, acute pulmonary edema, acute cardiac ischemia, chest pain, dyspnea, palpitations), or ophtalmological involvement (notably ischemic retinopathy or blurred vision)"}, "exclude": false}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "For women of childbearing potential: Effective contraception during the study and for at least 5 months after the last dose of treatment with eculizumab"}, "exclude": false}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Subject affiliated to a social security regimen"}, "exclude": false}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Subject having signed written informed consent"}, "exclude": false}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Atrophic kidneys with maximum length<8cm on recent (<1 month) renal ultrasound, CT scan, or renal MRI"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Contra-indication to eculizumab or renin angiotensin system blockers"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Solid organ or haematopoietic transplant"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "History (<1year) of active cancer or exposition to drugs associated with aHUS (< 3 months)"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Severe cognitive or psychiatric disorders, patients unable to give an informed consent"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "PCR SARS-CoV2 positive"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Pregnant or breastfeeding woman or ineffective contraception"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Persons deprived of their liberty by judicial or administrative decision"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Persons under legal protection (guardianship, curatorship)"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "High clinical suspicion of Complement-mediated aHUS (including familial history of aHUS)"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "High clinical suspicion of typical HUS (including Shiga Toxin-producing E. Coli infection) or Thrombotic thrombocytopenic purpura"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "High clinical suspicion of secondary HUS related to autoimmune disease (including lupus, scleroderma, antiphospholipid syndrome, ANCA vasculitis), or C3 glomerulopathy."}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "High clinical suspicion of recent hemorrhagic or ischemic stroke"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "ADAMTS 13<10%, HIV or HCV infection, positivity of 2 markers among: anticardiolipin IgG/antiBeta2 GP1 IgG/lupus anticoagulant, positivity of ANCA (ELISA PR3 or MPO)"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Active infection"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Subjects with unresolved Neisseria meningitidis infection"}, "exclude": true}, {"code": {"text": "Eligibility Criterion"}, "valueCodeableConcept": {"text": "Subjects refusing Neisseria meningitidis vaccination or refusing antibioprophylaxis with oracillin (In case of penicillin allergy, antibioprophylaxis with macrolide couldbeproposed according to ANSM recommendations (azithromycin or roxithromycin))"}, "exclude": true}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Brian S. Alper, MD, MSPH"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "CTIS2024-516402-32-00 Eligibility Criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper, MD, MSPH [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 346486. Revised 2025-05-15. Available at: https://fevir.net/resources/Group/346486. Computable resource at: https://fevir.net/resources/Group/346486#json."}], "meta": {"versionId": "3", "lastUpdated": "2025-05-15T06:47:17.698Z"}, "url": "https://fevir.net/resources/Group/346486", "id": "346486", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "description": "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide."}